Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chidamide Maintenance to Prevent Relapse After Allogeneic HSCT in Acute T-Lymphoblastic Leukemia/Lymphoma: A Multicenter Randomized Controlled Trial

NCT07774377 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07774377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chidamide Maintenance to Prevent Relapse After Allogeneic HSCT in Acute T-Lymphoblastic Leukemia/Lymphoma: A Multicenter Randomized Controlled Trial
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 15, 2026
Completion date
August 15, 2029
Enrollment
132 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia, t-cell lymphoblastic lymphoma